DRUG SCHEDULE 13G/A: SEC filing

Cormorant Asset Management, LP and Bihua Chen

Filed with the SEC on · accession 0001172661-26-005294

DRUG filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Cormorant Asset Management, LP and Bihua Chen filed an amended Schedule 13G reporting beneficial ownership of 800,000 common shares, or 8.11%, of Bright Minds Biosciences Inc. as of September 30, 2026. The stock moved -2.2% by the first close after the filing.

Summary of the filing

Cormorant Asset Management, LP and Bihua Chen filed an amended Schedule 13G reporting beneficial ownership of 800,000 common shares, or 8.11%, of Bright Minds Biosciences Inc. as of September 30, 2026. The filing is a passive investment disclosure and does not indicate any intent to influence control of the issuer.

Key details

Common shares beneficially owned$800K
Percentage of class beneficially ownedPCT 8
Reporting person / investment adviser to cormorant fundsCormorant Asset Management, LP
Issuer of the securitiesBright Minds Biosciences Inc.
Cormorant fund with right to receive dividends or proceeds from more than 5% of the sharesCormorant Global Healthcare Master Fund, LP
Managing member of cormorant asset management, lpBihua Chen

How DRUG stock reacted

Close before

$23.11

Nov 13, 2026

First close after

-2.16%

$22.61

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for DRUG, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for DRUG?

Click here

Frequently asked questions

What did DRUG file with the SEC on Nov 16, 2026?

DRUG filed a SCHEDULE 13G/A (SEC filing). Cormorant Asset Management, LP and Bihua Chen filed an amended Schedule 13G reporting beneficial ownership of 800,000 common shares, or 8.11%, of Bright Minds Biosciences Inc. as of September 30, 2026. The filing is a passive investment disclosure and does not indicate any intent to influence control of the issuer.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did DRUG stock react to this filing?

DRUG closed at $23.11 before the filing and $22.61 on Nov 16, 2026 (-2.16%).

Other DRUG SEC filings

Get alerts when DRUG files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days